Cullinan Oncology is a biopharmaceutical company. Co. is evaluating its primary candidate, CLN-081, in a trial in patients with non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations who have previously received platinum-based chemotherapy. Co.'s two other clinical stage programs include CLN-049, a bispecific T cell-engaging antibody targeting FLT3 and CD3 that is in an ongoing clinical trial for patients with relapsed or refractory acute myeloid leukemia; and CLN-619, a monoclonal antibody that stabilizes a tumor cell surface target, MICA/MICB, to promote an antitumor response via activation of both natural killer cells and certain T cells. The CGEM stock yearly return is shown above.
The yearly return on the CGEM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CGEM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|